The Claim
In high-risk patients with stable atherosclerosis who are already receiving statin therapy, the addition of evolocumab significantly reduces the risk of major adverse cardiovascular events, with consistent treatment effects across subgroups, including those with prior ischemic stroke; however, the magnitude of benefit may be attenuated in patients with prior stroke (hazard ratio 0.85, 95% CI 0.72–1.00).
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
For people with clogged arteries who are already on cholesterol drugs, adding a medicine called evolocumab helps lower their risk of heart problems — and it works pretty well even for those who've had a stroke before, though the benefit might be a bit smaller for them.
See the scientific wording
Among high-risk patients with stable atherosclerosis on statin therapy, evolocumab significantly reduces the composite cardiovascular endpoint, with consistent effects observed across subgroups including those with prior ischemic stroke, though the benefit may be attenuated in this subgroup (hazard ratio 0.85, 95% CI 0.72–1.00).
What the research says
1 studyThe study shows that adding evolocumab to statins helps reduce heart and blood vessel problems in high-risk patients, including those who've had a stroke before, just like the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.